Pace Life Sciences Boosts Biopharma Support With New Jersey Laboratory Acquisition

Pace® Life Sciences, LLC, a prominent contract development and manufacturing organization (CDMO), has recently expanded its operational footprint by acquiring a laboratory facility in Lebanon, New Jersey. This facility, previously operated by Whitehouse Analytical Laboratories and owned by Curia, another global CDMO, has been instrumental in fostering partnerships within the biopharma industry for over a decade. The acquisition is set to enhance Pace® Life Sciences' capabilities in providing comprehensive analytical services for drug development and commercialization.

Eric Roman, CEO of Pace®, expressed enthusiasm about the acquisition, highlighting its significance in bolstering the company's leadership in analytical services. He looks forward to collaborating closely with the New Jersey team to support pharma and biopharma clients more effectively. Philip Macnabb, CEO of Curia, acknowledged the specialized analytical services offered by the Lebanon site, praising the team's contributions while noting that these services were outside Curia's core focus areas. The decision to pass the baton to Pace®, according to Macnabb, aligns with Curia's strategy to concentrate on its strengths in discovering, developing, and manufacturing transformative medicines.

The addition of the New Jersey laboratory expands Pace® Life Sciences' network to nine sites, enhancing its capacity to support a broad range of analytical services. This includes formulation development and early-stage drug product manufacturing services. The facility is equipped for FDA-registered central laboratory services such as analytical chemistry, microbiology, container closure integrity testing (CCIT), sterility testing, and other essential packaging and delivery testing services.

Pace® Life Sciences is backed by Leonard Green & Partners and Aurora Capital Partners, showcasing strong financial and strategic support for its operations. The company is part of the larger Pace® organization, which aims to make the world a safer and healthier place through its contributions to the pharmaceutical and biotechnology industries.

Curia brings over three decades of experience as a CDMO, boasting an integrated network of 27 global sites and a workforce of over 3,500 employees. The organization partners with biopharmaceutical companies to bring life-changing therapies to market. Its offerings cover the entire drug development lifecycle from discovery through commercialization, supported by integrated regulatory and analytical capabilities. Curia's commitment spans across both biologics and small molecule drug substance and product manufacturing.

Pace® Life Sciences offers a comprehensive suite of contract CMC development, clinical trials materials manufacturing, regulatory compliance, consulting, and facility support services. With a network of GMP analytical testing laboratories and manufacturing support service centers, Pace® is dedicated to advancing client programs from clinical stages to commercialization efficiently. The organization prides itself on delivering high-quality services that ensure customer satisfaction across all business channels.

In summary, this strategic acquisition by Pace® Life Sciences not only enhances its service offerings but also strengthens its position as a leader in the analytical services sector within the biopharma industry. By integrating the expertise and capabilities of the New Jersey laboratory facility into its operations, Pace® is well-positioned to meet the evolving needs of its clients in drug development and commercialization.